Kory James Wentworth, Chief Financial Officer at Entrada Therapeutics, Inc. (TRDA), sold 15,976 shares at $12.25 ($196K) on 2026-03-04, disclosed to the SEC on 2026-03-06.
Seasonal sale ($196k) by Chief Financial Officer — this insider has traded TRDA in March in at least three consecutive prior years. Pattern-driven, low signal.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $12.25 | 7,988 | $98K | 50.0% |
| 2 | $12.25 | 7,988 | $98K | 50.0% |
| Total | $12.25 avg | 15,976 | $196K | 100% |
| Filing → |
| TRDA | SELL | 2025-11-24 | $178K | — | Filing → |
| TRDA | SELL | 2025-03-19 | $19K | — | Filing → |
| TRDA | SELL | 2024-12-03 | $120K | — | Filing → |